1. FDA Approval in Myeloma, Label Update in HER2+ Breast Cancer, Breakthrough Status in Prostate Cancer, and More
An FDA approval in multiple myeloma, a label update in breast cancer, a breakthrough therapy designation in prostate cancer, research grants awarded in rare diseases, and two trials in pediatric acute lymphoblastic leukemia stopped early due to benefit.more details...


2. J&J bags FDA breakthrough designation for prostate cancer drug
J&J bags FDA breakthrough designation for prostate cancer drug Could challenge rival PARP inhibitor Lynparza Janssen The FDA has granted Johnson & Johnson's PARP inhibitor niraparib a breakthrough therapy designation (BTD) in prostate cancer, helping it to make gains on rival Lynparza. more details...


3. FDA expands Erleada approval for prostate cancer
The FDA expanded the approval of apalutamide to include treatment of men with metastatic castration-sensitive prostate cancer. Apalutamide (Erleada, Janssen) — an oral androgen receptor inhibitor — already had been approved for the treatment of nonmetastatic castration-resistant prostate cancer. more details...


4. Prostate cancer: Eating this food may reduce your risk of developing the deadly disease
PROSTATE cancer is the most common type of cancer to be diagnosed amongst men in the UK, according to the NHS. It’s estimated there is around 47,000 new cases of the disease each year and 1.2 million new cases worldwide. With these worrying statistics, what food can you eat to help reduce your risk? more details...


5. FDA Green Lights Generic Drug for Certain Patients with Prostate Cancer
Glenmark Pharmaceuticals has received FDA approval for abiraterone acetate tablets USP, 250 mg, a generic version of Janssen's Zytiga tablets, 250 mg.1 Abiraterone acetate tablets are a type of hormone therapy used in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have already received chemotherapy containing docetaxel.2 more details...